Back to top
more

HealthEquity (HQY)

(Real Time Quote from BATS)

$91.05 USD

91.05
631,983

+0.04 (0.04%)

Updated Aug 6, 2025 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

HealthEquity (HQY) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended October 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

HealthEquity (HQY) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of 9.86% and 3.84%, respectively, for the quarter ended October 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Unlocking Q3 Potential of HealthEquity (HQY): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for HealthEquity (HQY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended October 2024.

Zacks Equity Research

Embecta Corp. (EMBC) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 12.50% and 2.50%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HealthEquity, Inc. (HQY) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

HealthEquity Gains 54.6% YTD: What's Driving the Stock?

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Strength Seen in HealthEquity (HQY): Can Its 3.5% Jump Turn into More Strength?

by Zacks Equity Research

HealthEquity (HQY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Sensus Healthcare (SRTS) delivered earnings and revenue surprises of 450% and 51.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Add HealthEquity Stock to Your Portfolio Now

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

The Beauty Health Company (SKIN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Beauty Health (SKIN) delivered earnings and revenue surprises of -25% and 1.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up

by Zacks Equity Research

Insulet's third-quarter performance benefits from the continued high demand for Omnipod 5.

Zacks Equity Research

AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls

by Zacks Equity Research

Amedisys, for the third quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.

Zacks Equity Research

MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

by Zacks Equity Research

Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.

Zacks Equity Research

TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket

by Zacks Equity Research

Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

Zacks Equity Research

BRKR Misses on Q3 Earnings, Cuts '24 View, Stock Up in Aftermarket

by Zacks Equity Research

Bruker delivers robust revenue growth in the third quarter despite soft general market conditions.

Zacks Equity Research

STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket

by Zacks Equity Research

STERIS' second-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of both margins is concerning.

Zacks Equity Research

HealthEquity, Inc. (HQY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

HealthEquity (HQY) Moves 9.8% Higher: Will This Strength Last?

by Zacks Equity Research

HealthEquity (HQY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

GMED Q3 Earnings Top, '24 Guidance Raised, Stock Gains in Aftermarket

by Zacks Equity Research

Globus Medical delivers massive sales and earnings growth in the third quarter of 2024. However, margins contract.

Zacks Equity Research

HSIC Q3 Earnings Top, Margins Down, Stock Gains in Premarket

by Zacks Equity Research

Henry Schein's third-quarter results reflect an improvement in sales trends in Technology and Value-Added Services business.

Zacks Equity Research

ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket

by Zacks Equity Research

Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.

Zacks Equity Research

IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket

by Zacks Equity Research

IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments.